Drug makers grounding salespeople as coronavirus impact on business spreads
In another sign that the coronavirus pandemic is fundamentally interrupting the way biopharma conducts business, drug makers are grounding the employees who market and sell their products to physicians and hospitals.
On Sunday, Amarin, the maker of the heart drug Vascepa, said it was implementing a two-week suspension of all “face-to-face interactions” between its salespeople and physician offices. The restriction will be in place until March 30.
Read Original Article: Drug makers grounding salespeople as coronavirus impact on business spreads »
